Cytoplasm

Proteintech Genomics Launches First Commercially Available Solution for the Detection of Intracellular Proteins for Single-Cell RNAseq Experiments

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Manufacturing, Other Health, Health, General Health, Other Science, Medical Devices, Research, Other Manufacturing, Genetics, Science, Genomics, Cytoplasm, Pander Multipro, Isotype, Protein, Multimedia, Antibody, Spatial analysis, Gene expression, Vaccine, Biology

This cocktail contains 53 antibodies against intracellular and cell surface proteins, plus 5 isotype controls.

Key Points: 
  • This cocktail contains 53 antibodies against intracellular and cell surface proteins, plus 5 isotype controls.
  • The pre-titrated cocktail is demonstrated to be compatible with the 10x Genomics® Chromium® Single Cell Gene Expression Flex product.
  • We have been working diligently to provide researchers with the ability to delve beyond the cell surface and provide a high resolution view of intracellular proteins in addition to cell surface proteins and gene expression.
  • While several groups have subsequently obtained believable signal from intracellular proteins coupled with single cell gene expression, the resulting data was suboptimal.

SOLA Biosciences Shares Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS at 22nd Annual NEALS Meeting

Retrieved on: 
Tuesday, October 3, 2023
Health, Health Technology, Genetics, Clinical Trials, Research, Science, Biotechnology, HSP70, DNA, Cytoplasm, ALS, Toxicity, Patient, SOLA, RNA, AAV, Sulfur, Pharmaceutical industry

SOLA Biosciences, a pioneer in innovative chaperone technology, will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in ALS, at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting held in Florida on October 5.

Key Points: 
  • SOLA Biosciences, a pioneer in innovative chaperone technology, will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in ALS, at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting held in Florida on October 5.
  • The compelling results from various behavioral tests provide strong support for the continued preclinical development of SOL-257 as a potential ALS therapeutic.
  • "Our findings underscore SOL-257 as a promising transformational therapy in ALS," expressed Dr. Akinori Hishiya, Chief Scientific Officer at SOLA.
  • The unmet medical need in ALS remains high, despite the current therapeutic landscape, and the prospect of a broadly applicable, one-time therapy brings new hope to the ALS community."

Kanazawa University research: Researchers identify the dynamic behavior of a key SARS-CoV-2 accessory protein

Retrieved on: 
Tuesday, September 26, 2023
Infection, Spontaneous, Urea, SARS-CoV-2, ORF6, Fever, COVID-19, Survival, Alcohol, Lipid, Polymer, Cytoplasm, Sodium dodecyl sulfate, Messenger, XXX, Behavior, The Journal of Physical Chemistry Letters, Protein, Journal, Sickness, Physical chemistry, Observation, Chiba University, Immune system, Environment, Virus, Factorization of polynomials, AFM, ORF, Disease, Kanazawa University, Microscope, Vaccine, COVID19

With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.

Key Points: 
  • With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.
  • "Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report.
  • However, the mechanism for this protein retention and transport disruption was not clear.
  • To shed light on these mechanisms the researchers first looked into what clues various software programs might give as to the structure of ORF6.

Kanazawa University research: Researchers identify the dynamic behavior of a key SARS-CoV-2 accessory protein

Retrieved on: 
Tuesday, September 26, 2023
Infection, Spontaneous, Urea, SARS-CoV-2, ORF6, Fever, COVID-19, Survival, Alcohol, Lipid, Polymer, Cytoplasm, Sodium dodecyl sulfate, Messenger, XXX, Behavior, The Journal of Physical Chemistry Letters, Protein, Journal, Sickness, Physical chemistry, Observation, Chiba University, Immune system, Environment, Virus, Factorization of polynomials, AFM, ORF, Disease, Kanazawa University, Microscope, Vaccine, COVID19

With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.

Key Points: 
  • With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.
  • "Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report.
  • However, the mechanism for this protein retention and transport disruption was not clear.
  • To shed light on these mechanisms the researchers first looked into what clues various software programs might give as to the structure of ORF6.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on: 
Tuesday, August 22, 2023
Membrane protein, DNA, MDM2, Headache, TP53, Somatic symptom disorder, Survival, NUP107, Enzyme, Cancer, Nuclear envelope, Brain, Cell Reports, Cytoplasm, Protein, Cell nucleus, Cell, Nausea, Diagnosis, Personality, NPC, Genome, Non-player character, Kanazawa University, Vaccine, Glioblastoma

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points: 
  • KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
  • Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
  • Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
  • Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on: 
Tuesday, August 22, 2023
Membrane protein, DNA, MDM2, Headache, TP53, Somatic symptom disorder, Survival, NUP107, Enzyme, Cancer, Nuclear envelope, Brain, Cell Reports, Cytoplasm, Protein, Cell nucleus, Cell, Nausea, Diagnosis, Personality, NPC, Genome, Non-player character, Kanazawa University, Vaccine, Glioblastoma

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points: 
  • KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
  • Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
  • Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
  • Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

ALS Finding a Cure, The ALS Association Partner to Reduce Time to Initial ALS Diagnosis

Retrieved on: 
Thursday, August 17, 2023
Massachusetts General Hospital, Trinity College, Neuron, Partnership, Drug development, Speech, Electroencephalography, Spinal cord, C9orf72, Quality of life, RNA, Research, Brain, Cell, Biomarker, Cytoplasm, Messenger, ALS Association, Brain cell, Harvard Medical School, Trinity College Dublin, The, Protein, Johns Hopkins University, Patient, Mass, Risk, EEG, Blood, Cancer, Medicine, Neurology, CSF, Diagnosis, Hospital, Early, ALS, Gene, Peptide, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Management

BOSTON and BOYNTON BEACH, Fla., Aug. 17, 2023 /PRNewswire/ -- ALS Finding a Cure® (ALSFAC) and The ALS Association announced today seven new grants worth a total of $2 million to support the development of early diagnostics for ALS.

Key Points: 
  • To receive an ALS diagnosis, patients must first undergo a battery of tests designed to rule out other conditions.
  • This is highly problematic because it can take a year – or sometimes even longer – for a person with ALS to receive the correct diagnosis.
  • To address this challenge, ALSFAC launched the Early ALS Diagnostics Initiative to identify promising molecular, digital, imaging, and electrophysiological diagnostic approaches for ALS.
  • After receiving a Partnership Grant from The ALS Association, ALSFAC was able to increase the number of projects supported by the initiative and expand its reach internationally.

New Preliminary Findings on Potential Response Indicator of Rakuten Medical's Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023

Retrieved on: 
Friday, June 30, 2023
CT, PIT, Society, PMID, SNMMI, Fluorescence, Molecular imaging, Society of Nuclear Medicine and Molecular Imaging, Clinical trial, Shimadzu, Cancer, PET, Head, Cell, Cytoplasm, Development, National Cancer Institute, Cooperative research and development agreement, Metabolism, Patient, Data analysis, Acquisition, Charles François Duhoux, SAN, Annual general meeting, HNSCC, Squamous-cell carcinoma, NCI, EPUB, NIH, Neck, Safety, 18F-FDG, Pharmaceutical industry, Medical imaging

SAN DIEGO, June 30, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting held from June 24 to 27.  ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (photoimmunotherapy: PIT) using an antibody-dye conjugate ASP-1929 with fluorescence imaging (ClinicalTrials.gov Identifier: NCT05182866) in patients with operable primary or recurrent head and neck squamous cell carcinoma (HNSCC) or cutaneous squamous cell carcinoma (cuSCC).  

Key Points: 
  • ASP-1929-103 is the very first clinical trial of Alluminox treatment in operable cancer.
  • As part of this trial, early time point (1 day) 18F-FDG PET/CT imaging was investigated as a potential response indicator of Alluminox treatment.
  • The preliminary, descriptive imaging analysis based on interim evaluation of 6 patients in ASP-1929-103 study presented during the meeting showed that 18F-FDG PET/CT imaging demonstrates a therapeutic response 1 day after Alluminox treatment using ASP-1929.
  • ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (PIT) using an anti-EGFR antibody-dye conjugate, ASP-1929 with fluorescence imaging in patients with operable primary or recurrent HNSCC or cuSCC.

OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences

Retrieved on: 
Thursday, June 15, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, NETS, Bispecific monoclonal antibody, Collaboration, Drug development, Cell death, CD127, TNF, Neutrophil, IL-7, Chromatin, Survival, INSERM, End organ damage, Interleukin, Antibody, Neoplasm, Research, Inflammation, Cytoplasm, Fibrosis, Patient, Translational research, Clinical & Translational Immunology, Neutrophil extracellular traps, ISIN, Mouse, Mnemos EP, Poster, Cytokine, PD-1, TRIM21, Conference, Interferon, Pharmaceutical industry, Vaccine, Transplant

Dr Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, commented: “We are very proud to share our latest scientific advances on our innovative pre-IND research programs with the international scientific community.

Key Points: 
  • Dr Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, commented: “We are very proud to share our latest scientific advances on our innovative pre-IND research programs with the international scientific community.
  • We are looking forward to progressing these programs with strategic partners into clinical stage”.
  • Dr Aurore Morello, Head of Research of OSE Immunotherapeutics, said: “The latest data featured in our communications highlight the value and therapeutic potential of our pre-IND assets.
  • BiCKI®-IL-7, our bispecific anti-PD1/IL-7 program, presents an innovative cytokine approach, selectively targeting tumor-specific T-cells to improve the quality and durability of memory T-lymphocyte responses.

Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023

Retrieved on: 
Monday, May 8, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, LMTK3, Tissue, DNA, AACR, Histology, Eureka, Friends, Gynecologic cancer disparities in the United States, Survival, Eurostar, Woman, Cytoplasm, Mother, Patient, Annual general meeting, Spouse, Diagnosis, American Association for Cancer Research, Ovarian cancer, Therapy, Death, Gene, DNA repair, Medical imaging

“While survival rates for ovarian cancer are creeping up to the 50% level, it is clear that the vast majority of women are diagnosed too late,” said Sanj Singh , CEO of Temple Therapeutics.

Key Points: 
  • “While survival rates for ovarian cancer are creeping up to the 50% level, it is clear that the vast majority of women are diagnosed too late,” said Sanj Singh , CEO of Temple Therapeutics.
  • Risk of death among ovarian cancer patients with more cytoplasmic than nuclear LMTK3 levels was particularly high during the first year after diagnosis.
  • We knew then this may be a game changer for ovarian cancer because it was present in all major subtypes.
  • “The addition of a companion diagnostic for early detection, therapeutic impact, and disease progression injects much-needed hope for ovarian cancer patients.